![Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry | Scientific Reports Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-92722-x/MediaObjects/41598_2021_92722_Fig1_HTML.png)
Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry | Scientific Reports
![Frontiers | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | Neurology Frontiers | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | Neurology](https://www.frontiersin.org/files/MyHome%20Article%20Library/696807/696807_Thumb_400.jpg)
Frontiers | Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue | Neurology
![Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1601469710/Copaxone.jpg/Copaxone.jpg?VersionId=PhbA.kpjNFb3A_uch5krsTbbBmdM_mNL)
Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma
![Neu gegründete Business Unit "Copaxone(R) und innovative Produkte" bei österreichischer TEVA Tochter ratiopharm | ratiopharm Arzneimittel Vertriebs GmbH, 12.10.2011 Neu gegründete Business Unit "Copaxone(R) und innovative Produkte" bei österreichischer TEVA Tochter ratiopharm | ratiopharm Arzneimittel Vertriebs GmbH, 12.10.2011](https://www.ots.at/anhang/2011/10/12/OBS/OBS_20111012_OBS0015_galerie.jpg)
Neu gegründete Business Unit "Copaxone(R) und innovative Produkte" bei österreichischer TEVA Tochter ratiopharm | ratiopharm Arzneimittel Vertriebs GmbH, 12.10.2011
![Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | Fierce Pharma Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1550072420/K%C3%A5re_Schultz.jpg/K%C3%A5re_Schultz.jpg?VersionId=AkAld2.fqNUOre49lDIi3.nl41ZccSpR)
Teva forecasts worse-than-expected 'trough year' as generics hammer MS drug Copaxone | Fierce Pharma
![Takeda Pharmaceutical: Arzneimittelzulassung für subkutane Injektionsspritze mit 20 mg Copaxone® in Japan: Arzneimittel zur Behandlung der multiplen Sklerose | Business Wire Takeda Pharmaceutical: Arzneimittelzulassung für subkutane Injektionsspritze mit 20 mg Copaxone® in Japan: Arzneimittel zur Behandlung der multiplen Sklerose | Business Wire](https://mms.businesswire.com/media/20150928006525/de/482645/23/BrandSymbol_Dakiyama_line_Rd.jpg)
Takeda Pharmaceutical: Arzneimittelzulassung für subkutane Injektionsspritze mit 20 mg Copaxone® in Japan: Arzneimittel zur Behandlung der multiplen Sklerose | Business Wire
![MS hat viele Symptome": Division 4 entwickelte Kampagne zum Welt-Multiple- Sklerose-Tag - Werbung - derStandard.at › Etat MS hat viele Symptome": Division 4 entwickelte Kampagne zum Welt-Multiple- Sklerose-Tag - Werbung - derStandard.at › Etat](https://i.ds.at/zAVqDg/rs:fill:750:0/plain/2022/05/27/ms.jpg)